Changed route of immunization dramatically improves efficacy of TB vaccine in animals

Thursday, Jan. 2, 2020 Changed route of immunization dramatically improves efficacy of TB vaccine The world's only licensed tuberculosis (TB) vaccine was developed a century ago; it can protect infants from one form of the disease but is not very good at preventing the more common and more deadly pulmonary TB. Now, NIAID researchers and their colleagues have shown that delivering the vaccine intravenously dramatically improves its ability to protect rhesus macaques from infection following exposure to TB-causing bacteria. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID). This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107